ReveraGen BioPharma, Inc. today announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy.
{iframe}http://www.reveragen.com/reveragen-announces-first-patient-enrollment-in-international-pivotal-trial-of-vamorolone-in-duchenne-muscular-dystrophy/{/iframe}